Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML2710

Sigma-Aldrich

ZCZ011

≥98% (HPLC)

Synonym(s):

6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole, 6-Methyl-3-[2-nitro-1-(2-thienyl)ethyl]-2-phenyl-1H-indole, ZCZ 011, ZCZ-011

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$80.75
25 MG
$345.00

$80.75

List Price$85.00Save 5%
Web-Only Promotion

Available to ship onMay 01, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
$80.75
25 MG
$345.00

About This Item

Empirical Formula (Hill Notation):
C21H18N2O2S
CAS Number:
1998197-39-9
Molecular Weight:
362.44
MDL number:
MFCD31692973
UNSPSC Code:
12352200
NACRES:
NA.77

$80.75

List Price$85.00Save 5%
Web-Only Promotion

Available to ship onMay 01, 2025Details

Request a Bulk Order

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[s]1c(ccc1)C(C[N+](=O)[O-])c2c3c([nH]c2c4ccccc4)cc(cc3)C

InChI key

RJSPNRDBWHHFMH-UHFFFAOYSA-N

Biochem/physiol Actions

Brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that blocks neuropathic pain without cannabimimetic side-effects.
ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011 potentiates AEA-stimulated GTPγS binding (Emax = 46.5% without vs. 115.2% with 100 nM ZCZ011; mouse brain membranes) and cellular signaling (β-arrestin Emax = 100% without vs.157% with 100 nM ZCZ011, pERK pIC50 = 6.5 without vs. 8.3 with 10 nM ZCZ011; hCB1 cells). ZCZ011 exhibits antinociceptive efficay in murine chronic constriction injury (CCI) model of neuropathic pain & carrageenan model of inflammatory pain (40 mg/kg i.p.) without cannabimimetic side-effects.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chih-Chung Tseng et al.
Journal of medicinal chemistry, 62(10), 5049-5062 (2019-05-06)
The first generation of CB1 positive allosteric modulators (e.g., ZCZ011) featured a 3-nitroalkyl-2-phenyl-indole structure. Although a small number of drugs include the nitro group, it is generally not regarded as being "drug-like", and this is particularly true for aliphatic nitro
K R Trexler et al.
Pharmacology, biochemistry, and behavior, 177, 27-33 (2019-01-01)
Recently, multiple compounds have been synthesized that target the allosteric binding site(s) of CB1. These CB1 positive allosteric modulators may capture the benefits of cannabinoid receptor activation without unwanted psychoactive effects, such as sedation. For example, ZCZ011 blocks neuropathic pain
Jose Mitjavila et al.
Pharmacological research, 129, 475-481 (2017-11-22)
The cannabinoid signaling system is found throughout the CNS and its involvement in several pathological processes makes it an attractive therapeutic target. Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development
Noureldin Saleh et al.
Angewandte Chemie (International ed. in English), 57(10), 2580-2585 (2018-01-10)
The cannabinoid CB1 receptor (CB1R) is an abundant metabotropic G-protein-coupled receptor that has been difficult to address therapeutically because of CNS side effects exerted by orthosteric drug candidates. Recent efforts have focused on developing allosteric modulators that target CB1R. Compounds
Kaavya Krishna Kumar et al.
Cell, 176(3), 448-458 (2019-01-15)
Cannabis elicits its mood-enhancing and analgesic effects through the cannabinoid receptor 1 (CB1), a G protein-coupled receptor (GPCR) that signals primarily through the adenylyl cyclase-inhibiting heterotrimeric G protein Gi. Activation of CB1-Gi signaling pathways holds potential for treating a number of
View All Related Papers

Questions

  1. Does it specifically target the CB1 receptor?

    1 answer

    1. As shown on the product detail page, Product ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011 potentiates AEA-stimulated GTP?S binding (Emax = 46.5% without vs. 115.2% with 100 nM ZCZ011; mouse brain membranes) and cellular signaling (?-arrestin Emax = 100% without vs.157% with 100 nM ZCZ011, pERK pIC50 = 6.5 without vs. 8.3 with 10 nM ZCZ011; hCB1 cells). ZCZ011 exhibits antinociceptive efficay in murine chronic constriction injury (CCI) model of neuropathic pain & carrageenan model of inflammatory pain (40 mg/kg i.p.) without cannabimimetic side-effects.

      Identity testing is performed to be sure the product is ZCZ011 but test functions are not determined. The end-user may want to consult with literature to get more information about ZCZ011.

      Helpful?

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service